Clinical Trials
604
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (338 trials with phase data)• Click on a phase to view related trials
The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)
- Conditions
- Frontal Fibrosing AlopeciaCicatricial Alopecia
- Interventions
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT07190534
- Locations
- 🇳🇱
Erasmus MC University Medical Center, Rotterdam, South Holland, Netherlands
ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer
- Conditions
- Rectal Cancer
- Interventions
- Drug: Adjuvant chemotherapy
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 103
- Registration Number
- NCT07188025
Piezosurgery Versus Conventional Techniques in Orthognathic Surgery
- Conditions
- Orthognathic Surgical ProceduresPiezoelectric Technique
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 70
- Registration Number
- NCT07174193
- Locations
- 🇳🇱
Anna Ziekenhuis, Geldrop, Netherlands
🇳🇱Erasmus Medical Center, Rotterdam, Netherlands
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)
- Conditions
- Hilar CholangiocarcinomaCommon Bile Duct NeoplasmsIntrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaPerihilar CholangiocarcinomaAdenocarcinoma of Biliary Tract
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 250
- Registration Number
- NCT07161869
- Locations
- 🇳🇱
Erasmus MC University Medical Center, Rotterdam, South Holland, Netherlands
Surveillance of Respiratory Viruses in Healthcare and Animal Workers
- Conditions
- Respiratory Viruses
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 250
- Registration Number
- NCT07156890
- Locations
- 🇳🇱
ErasmusMC, Rotterdam, South Holland, Netherlands
- Prev
- 1
- 2
- 3
- 4
- 5
- 89
- Next
News
AIM ImmunoTech Reports Promising Mid-Year Results from Phase 2 Pancreatic Cancer Combination Therapy Study
AIM ImmunoTech's Phase 2 DURIPANC study evaluating Ampligen combined with AstraZeneca's Imfinzi shows encouraging safety and efficacy signals in metastatic pancreatic cancer patients post-FOLFIRINOX treatment.
Egetis Therapeutics Advances Toward US NDA Submission for Tiratricol Following FDA Breakthrough Therapy Designation
The FDA granted Breakthrough Therapy Designation to Egetis Therapeutics' tiratricol in July 2025 for treating MCT8 deficiency, based on survival data showing significant improvement in treated versus untreated patients.
€26.2 Million GREG Initiative Launches to Transform Real-World Evidence Practices Across Europe
The GREG initiative, a five-year €26.2 million public-private partnership, has launched to advance Real-World Evidence practices for medicines and medical devices evaluation across Europe.
Socioeconomic Factors and Parental Smoking Linked to Worse MS Outcomes in Children
Children from socioeconomically disadvantaged backgrounds show more severe brain inflammation and tissue loss when diagnosed with multiple sclerosis, according to a new study published in Neurology.
AIM ImmunoTech Advances to Phase 2 Trial of Ampligen-Imfinzi Combination for Late-Stage Pancreatic Cancer
Safety Committee grants approval for Phase 2 portion of AIM ImmunoTech's Phase 1b/2 trial evaluating Ampligen in combination with AstraZeneca's Imfinzi for late-stage pancreatic cancer treatment.